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ABSTRACT
Background    Previously, we had performed a clinical 
study using human leukocyte antigen (HLA)-A24-bind-
ing peptide vaccines containing a combination of novel 
cancer-testis antigens and anti-angiogenic peptides de-
rived from DEPDC1, URLC10, FOXM1, KIF20A and 
VEGFR1 for advanced gastric cancer (AGC) patients 
who were refractory to chemotherapy. We applied the 
cocktail vaccine to the combination therapy with S-1 for 
patients with AGC as a post-operative adjuvant therapy 
and performed this clinical pilot study. 
Methods    AGC patients who had curative surgery and 
were classified as pathologically stage III were enrolled. 
At each 6-week treatment cycle, patients received week-
ly subcutaneous administration of the cocktail vaccine 
with 5 continuous injections and one break for the first 
4 cycles and with bi-weekly injections for the following 
4 cycles. S-1 (80 mg/m2) was administered orally for 
4 weeks with 2-week rest for all 8 cycles. The primary 
endpoint was the safety of the combination therapy and 
the secondary was the relative dose intensity for S-1. 
Results    Fourteen patients were enrolled. Six patients 
with HLA-A*2402 had received S-1 plus the cocktail 
vaccine as an adjuvant therapy and the remaining 8 
had S-1 monotherapy for eight cycles. Five out of 6 pa-
tients subjected to the combination group completed the 
therapy and one patient discontinued because of Grade 
3 injection-site reaction. No adverse events of grade 3 
or higher were observed except injection-site reactions 
shown in 5 out of 6 patients who had vaccine therapy. 
The mean and median relative dose intensities for S-1 
were 75.5% and 88% in the combination group and 67% 
and 80.5% in S-1. 
Conclusion    The vaccine therapy combined with S-1 
was manageable and safe adjuvant therapy for stage III 
gastric cancer. Furthermore, the optimal relative dose 
intensity of S-1 was achieved in combination group, al-
though the injection-site reaction should be considered. 
Key words    adjuvant therapy; gastric cancer; immuno-
therapy; peptide vaccine; S-1
Gastric cancer is the fifth most common malignancy and 
the third leading cause of cancer-related death world-
wide.1 In Japan, gastric cancer is the third-leading cause 
of death for both men and women.2 The only curative 
treatment for gastric cancer is radical gastrectomy with 
regional lymph node dissection. However, recurrence 
rates of advanced gastric cancer (AGC) are still high 
(40–80%)3, 4 and the adjuvant chemotherapy have been 
proposed even after curative resection to improve patient 
survival. Meta-analyses have shown that adjuvant che-
motherapy is effective and provides a significant surviv-
al benefit for patients with advanced gastric cancer.5–10 
Postoperative adjuvant chemotherapy with S-1 for stage 
II or III AGC prolonged overall survival and relapse-free 
survival with the Adjuvant Chemotherapy Trial of S-1 
for Gastric Cancer (ACTS-GC).11 According to the mul-
ticenter trial, adjuvant chemotherapy with S-1 for gastric 
cancer of stage II or III has been considered as a stan-
dard treatment in Japan. However, the efficacy of S-1 is 
still limited, with a 5-year overall survival rate of 67.1% 
for patients with stage IIIA disease and 50.2% for pa-
tients with stage IIIB disease.11 Also, the treatment ben-
efit of S-1 adjuvant chemotherapy seems to be smaller in 
stage IIIA or stage IIIB disease than in stage II disease 
comparing to the surgery alone in ACTS-GC study.11 
Thus, the treatment for patients with stage III disease 
needs further improvement. Several studies have been 
conducted to explore combination chemotherapy as ad-
juvant chemotherapy for gastric cancer. The CLASSIC 
study compared surgery alone and surgery plus adjuvant 
therapy with capecitabine and oxaliplatin in patients who 
had undergone curative resection of stage II, IIIA, or 
IIIB gastric cancer with D2 lymph node dissection. The 
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3-year disease-free survival as the primary endpoint was 
significantly improved with capecitabine and oxaliplatin 
therapy.12 In Japan, a feasibility study was conducted to 
investigate the tolerability of adjuvant therapy with S-1 
and cisplatin (SP). In that study, because of toxic effects 
observed mainly during the first cycle of SP therapy, 
the treatment completion rate was lower than expected. 
Therefore, the treatment schedule was revised during 
the study period to include S-1 monotherapy in the first 
cycle.13 
 After identification of tumor associated antigens, such 
as the melanoma-associated antigen (MAGE) family in 
1991, cancer immunotherapy has become a promising 
approach to fight cancer with minimum toxicity.14, 15 Re-
cently, several clinical trials using peptide vaccine ther-
apy targeting cancer-specific antigen peptides have been 
performed in the world and suggested improvement in 
patient survival.16–18 We previously performed a clinical 
trial using human leukocyte antigen (HLA)-A24-bind-
ing peptide vaccines containing a combination of novel 
cancer-testis antigens and anti-angiogenic peptides for 
AGC. In the study, 35 AGC patients who had shown 
resistance to the standard therapy were enrolled and 
were treated with vaccine therapy targeted for multiple 
peptides derived from DEPDC1, URLC10, FOXM1, KI-
F20A and VEGFR1. In conclusion, the peptide cocktail 
vaccine therapy was found to be safe and is expected to 
induce specific T cell responses frequently in patients 
with AGC.19
 In this study, we conducted a pilot study to evaluate 
the feasibility of the peptide cocktail vaccine combined 
with S-1 in the adjuvant treatment for curatively resected 
AGC patients.
MATERIALS AND METHODS
Patient eligibility 
Patients who had curative gastrectomy with D2 lymph-
adenectomy and whose pathological stage was classified 
as Stage IIIA, IIIB, or IIIC were enrolled in this trial at 
the Department of Surgery, Osaka Medical Center for 
Cancer and Cardiovascular Diseases. The following were 
the other main inclusion criteria: i) Eastern Cooperative 
Oncology (ECOG) performance status of 0–1; ii) age be-
tween 20 years and 79 years; iii) adequate bone-marrow, 
cardiac, pulmonary, hepatic and renal functions includ-
ing leukocyte count 3,000-10,000/mm3, platelet count > 
75,000/mm3, hemoglobin level > 8.0 g/dL, aspartate ami-
notransferase and alanine aminotransferase < 100 U/
L, total bilirubin < 1.5, and creatinine: no more than 1.5 
mg/dL; iv) signed informed consent was obtained. The 
main exclusion criteria were: i) the presence of another 
serious disease such as uncontrolled diabetes, hepatic 
disorder, cardiac disease, or hemorrhage/bleeding; ii) 
pregnant or breast-feeding woman; iii) patients who 
planned to become pregnant during the study period; iv) 
symptomatic infectious disease; v) need for concurrent 
treatment with steroids or immunosuppressive agents; 
vi) uncontrolled other malignant disease; vii) unhealed 
wound; viii) intestinal obstruction or interstitial pneu-
monia; ix) decision of unsuitableness by the principal 
investigator or physician in charge. 
Study design
This study was a pilot study on the combination of S-1 
chemotherapy and cancer vaccine therapy as a post-op-
erative adjuvant setting. All enrolled patients were tested 
HLA-A typing as a screening for enrollment and those 
with HLA-A*2402 received the combination therapy. 
Patients with other HLA-A genotypes had a standard 
chemotherapy with S-1 as a control. The HLA-A*2402 
restricted epitope peptide cocktail containing peptides 
for FOXM1, URLC10, KIF20, DEPDC1 and VFGFR1 
each at a dose of 1 mg were prepared in incomplete 
Freund’s adjuvant (Montanide ISA-51VG, SEPPIC, Par-
is, France) and injected subcutaneously in the inguinal 
region of the patients weekly. One treatment cycle con-
sisted of 5 injections on days 1, 8, 15, 22, and 29 with 
one week rest. The primary endpoint was the safety of 
this combination therapy containing the peptide cocktail 
vaccine. The secondary endpoint was the relative dose 
intensity for S-1 in the combination therapy. Toxicities 
were assessed by the Common Terminology Criteria for 
Adverse Events version 4.0 (CTCAE ver. 4.0).
 This trial was approved by the Ethics Committees 
of Osaka Medical Center for Cancer and Cardiovascular 
Diseases (approval number 1209055041) and carried out 
in accordance with the Helsinki declaration on experi-
mentation on human subjects.
Peptides 
HLA-A*2402-restricted FOXM1-262 (IYTWIED-
HF), URLC10-177 (RYCNLEGPPI)20, DEPDC1-294 
(EYYELFVNI)21, KIF20A-66 (KVYLRVRPLL)22 and 
VEGFR1-1084 (SYGVLLWEIF)23 peptides were syn-
thesized by the American Peptide Company (Sunnyvale, 
CA) according to a standard solid-phase synthesis meth-
od and purified by reversed-phase high-performance liq-
uid chromatography (HPLC).19 The purity (> 90%) and 
identity of the peptides were determined by analytical 
HPLC and mass spectrometry, respectively. 
RESULTS
Patient characteristics
Fourteen patients were enrolled in this trial between Oc-
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tober 2012 and Jun 2014. Table 1 shows the patient char-
acteristics at study entry. Six patients with HLA-A*2402 
genotype were allocated to the combination therapy of 
vaccine plus S-1 and the remaining 8 including 1 patient 
with HLA-A*2402 genotype were to S-1 mono-therapy. 
The patient with HLA-matched genotype refused to 
have vaccine therapy and was converted to S-1 mono-
therapy. They included 11 males and 3 females. All 
patients were performed with curative surgery including 
total gastrectomy in 5 patients and partial gastrectomy 
in 9. All patients were classified as pathologically stage 
III after surgery. 
Toxicity
Table 2 lists the toxicity profile recorded during the ad-
juvant therapy after surgery. The therapy was well-toler-
ated without any severe adverse events associated with 
the therapy except for 5 patients with the combination 
therapy who showed grade 3 injection-site reaction. 
Representative injection-site reactions are shown in Fig. 
1. The Grade 2 skin reaction is shown in Fig. 1A and the 
Grade 3 skin ulceration is shown in Fig. 1B. 
Feasibility
Table 3 summarized the therapy 
intensities in both groups. The 
mean and median number of vac-
cine injection was 26.5 and 29 in 
the combination therapy group. 
One patient discontinued the 
vaccine therapy after 2 cycles (10 
injections) due to Grade 3 skin re-
action and discontinued S-1 ther-
apy after 4 cycles due to patient 
refuse. The relative dose intensity 
for one-year S-1 was satisfactory 
in both groups. The mean (median) 
relative dose intensity for S-1 were 
75.5% (88%) in the combination 
therapy group and 67% (80.5%) in 
the S-1 monotherapy group. One 
patient discontinued S-1 due to 
Table 1. Patient characteristics enrolled in this trial
Total S-1 + vaccine S-1
n = 14 n = 6 n = 8
Age (years) 58.5 (40–71) 61.5 (54–71) 55 (40–71)
Gender (Male/Female) 11/3 6/0 5/3
Performance Status (0/1) 0/14 0/6 0/8
HLA-A*2402 (+/–) 7/7 6/0 1/7
Surgery (Total/Partial) 5/9 3/3 2/6
pStage (IIIA/IIIB/IIIC) 5/7/2 1/3/2 4/4/0
pT stage (T2/T3/T4a/T4b) 1/10/2/1 0/3/2/1 1/7/0/0
pN stage(N0/N1/N2/N3a/N3b) 1/0/4/6/3 1/0/1/2/2 0/0/3/4/1
Number of LN metastasis 7 (0–32) 11 (0–23) 7 (4–32)
HLA, human leukocyte antigen; LN, lymph node; pN, patholog-
ical Nodal stage; pStage, pathological Stage; pT, pathological T 
stage.  
Table 2. Toxicity profile
S-1 + vaccine S-1
n = 6 n = 8
Grade Grade
1 2 3 4 1 2 3 4
Injection-site reaction 0 1 5 / – – – /
Leukopenia 0 1 0 0 0 0 0 0
Neutropenia 0 1 0 0 0 0 0 0
Diarrhea 2 1 0 0 2 2 0 0
Anorexia 1 1 0 0 2 2 0 0
Fatigue 0 1 0 0 0 1 0 0
Stomatitis 1 0 0 0 1 1 0 0
Increase in AST/ALT 0 0 0 0 0 0 0 0
Increase in creatine 0 0 0 0 0 0 0 0
Fever 0 0 0 0 0 0 0 0
Flu-like symptoms 0 0 0 0 1 0 0 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
Fig. 1. Representative injection-site reactions in the combination 
therapy group.
A: Grade 1 skin redness was observed. B: Grade 3 skin ulceration was observed.
A B
Table 3. Clinical and immunological outcomes
S-1 + vaccine S-1
n = 6 n = 8
Number of vaccine injection
Mean (Median)
26.5 (29) 0
Relative dose intensity for S-1
Mean (Median)
75.5% 67%
(88%) (80.5%)
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para-aortic lymph node recurrence within one year and 
one patient did due to patient refuse in S-1-monotherapy 
group. 
DISCUSSION
The prognosis of pathologically stage III patients with cu-
rative gastrectomy is not satisfactory even having adjuvant 
therapy with S-1.11 Therefore, the combination chemother-
apy has been developed and several clinical trials have 
been performed.12, 13, 24 However, toxicities of the combi-
nation chemotherapy reduced the completion rate of the 
therapy and some modifications of the treatment schedule 
and optimal management of adverse events were needed 
to increase the completion rate.13, 24 Therefore, less toxic 
and more effective adjuvant treatment should be devel-
oped for such kind of AGC patients.
 Previously, we developed a cancer vaccine therapy 
with multiple peptides specific for AGC and we applied 
it for AGC patients who had shown resistance to the 
standard therapy as a monotherapy.19 According to the 
study, the cocktail vaccine using a combination of mul-
tiple peptides (DEPDC1, FOXM1, KIF20, URLC10, 
and VEGFR1) were well tolerated for AGC patients. 
Furthermore, specific cytotoxic T lymphocyte (CTL) 
responses for these five peptide antigens were frequently 
observed in the peripheral blood of patients and patients 
who showed the specific CTL responses induction tend-
ed to have better prognosis than those with no CTL in-
duction. 
 In this study, we applied the cocktail vaccine com-
bined with S-1 to the post-operative adjuvant therapy for 
pathologically stage III AGC patients. This study was a 
pilot study to examine the safety and feasibility of the 
combination therapy as a post-operative adjuvant treat-
ment. The combination therapy was safe and feasible 
in the completion rate of S-1 and vaccine, although the 
injection-site reaction should be cared during treatment. 
In our previous study, specific CTL responses against 5 
peptides in HLA-matched AGC patients were frequent-
ly observed: 55% of patients showed specific response 
against VEGFR1, 60% against DEPDC1 and KIF20A, 
90% against URLC10 and 100% against FOXM1. In-
jection-site reaction was shown in 26 (67%) out of 24 
patients with HLA-A*2402. In this study, 5 (83%) out of 
6 patients with HLA-matched genotype showed injec-
tion-site reaction. Therefore, although immunological 
responses against peptides had not been examined in 
this study, high frequent immunological responses might 
be induced in patients having adjuvant peptide vaccines 
even combined with S-1 chemotherapy. Miyazawa et 
al. conducted phase II clinical trial using the peptide 
vaccines including KIF20A (OCV-C01) and chemother-
apy with gemcitabine for surgically resected pancreatic 
cancer as post-operative adjuvant treatment.25 The study 
demonstrated that the combination therapy was tolerable 
and patients with KIF20A-specific CTL responses had 
shown significantly better disease-free survival than 
those without responses. In conclusion, the combination 
therapy of OCV-C01 and gemcitabine were promising, 
however, the clinical benefit of the therapy should be 
demonstrated by a randomized controlled trial. The ad-
juvant vaccine combined with chemotherapeutic agent 
might be a promising strategy for surgically resected 
solid malignancies.
 There are several limitations in this study. First, we 
haven’t performed dose escalation testing for peptide 
dose used in the combination therapy with S-1 and we 
have used the same dose of our previous study with the 
same cocktail vaccine used for AGC as a mono-therapy. 
The “3+3 design” should have been used for decision 
of optimal dose based upon the dose limiting toxicity; 
however, in cancer peptide vaccine therapy, it is difficult 
to identify the maximum tolerated dose because of the 
safety profile of vaccine therapy. Second, this study is an 
early exploratory study and showed no clinical benefit of 
the combination therapy. 
 In conclusion, the peptide cocktail vaccine com-
bined with S-1 was tolerable and further clinical studies 
are essential to demonstrate the clinical benefit of this 
treatment.
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